simvastatin has been researched along with Kidney Diseases in 28 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (7.14) | 18.2507 |
| 2000's | 14 (50.00) | 29.6817 |
| 2010's | 10 (35.71) | 24.3611 |
| 2020's | 2 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| de Fijter, JW; Dekker, FW; Dekkers, OM; Esmeijer, K; Hoogeveen, EK | 1 |
| Fras, Z; Mikhailidis, DP | 1 |
| Garg, A; Kaur, S; Kaushal, N | 1 |
| Ali, MC; Li, Z; Liu, J; Qi, W; Qiu, H; Tian, L; Wang, H; Wu, Q; Wu, W | 1 |
| Aschmann, HE; Kaufmann, M; Puhan, MA; Yebyo, HG | 1 |
| Aslani, P; Ayoub, R; Gelissen, IC; Moles, R; Nguyen, HL; Tiao, DK | 1 |
| Li, Q; Sun, S; Wang, C; Xu, Y; Zhen, J | 1 |
| Ali, RM; Alkaraki, AK; Mhaidat, NM; Shotar, AM | 1 |
| Bai, Y; Chan, C; Chang, X; Cheng, N; Cheng, Z; Lu, Y; Zhao, Y | 1 |
| Al Shohaib, S; Bahlas, S; Waness, A | 1 |
| Li, Q; Wang, L; Yang, X; Zhang, W | 1 |
| Arredondo-García, JL; Bojorquez-Ochoa, A; García-de-la-Puente, S; Gutiérrez-Castrellón, P; Maya, ER; Pérez-Martínez, Mdel P | 1 |
| Dai, DZ; Dai, Y; Luo, L; Zheng, YF | 1 |
| Teramoto, T | 1 |
| Doi, K; Fujita, T; Hamasaki, Y; Ijichi, H; Maeda-Mamiya, R; Noiri, E; Okamoto, K; Seki, G | 1 |
| Al Elaiwi, AM; Al-Asmari, AK; Al-Otaibi, KE; Tariq, M | 1 |
| Cressman, MD; Harris, S; Hutchinson, HG; Pears, JS; Vidt, DG | 1 |
| Boulday, G; Charreau, B; Coupel, S; Leboeuf, F; Soulillou, JP | 1 |
| Davis, NA; Inman, SR; Lukaszek, VA; Mazzone, ME; Olson, KM; Yoder, KN | 1 |
| Altmann, P; Armitage, J; Baigent, C; Baxter, A; Cairns, HS; Collins, R; Foley, RN; Frighi, V; Kourellias, K; Landray, M; Leaper, C; Ratcliffe, PJ; Rogerson, M; Scoble, JE; Tomson, CR; Warwick, G; Wheeler, DC | 1 |
| Krane, V; Wanner, C | 1 |
| Adu, D; Altmann, P; Armitage, J; Baigent, C; Ball, S; Baxter, A; Blackwell, L; Cairns, HS; Carr, S; Collins, R; Kourellias, K; Landray, M; Leaper, C; Rogerson, M; Scoble, JE; Tomson, CR; Warwick, G; Wheeler, DC | 1 |
| Chade, AR; Lerman, A; Lerman, LO; Mushin, OP; Napoli, C; Zhu, X | 1 |
| Alican, I; Ercan, F; Gedik, N; Işeri, S; Yüksel, M | 1 |
| Carpi, A; Consani, C; Filippi, C; Giovannini, L; Manca-Rizza, G; Mantuano, E; Panichi, V; Paoletti, S; Santi, S; Tramonti, G | 1 |
| Chello, M; D'Ambrosio, A; Di Sciascio, G; Nusca, A; Pasceri, V; Patti, G; Vetrovec, GW | 1 |
| Field, MJ; Johnson, DW; Pollock, CA; Saunders, HJ | 1 |
| Cao, Z; Cooper, ME; Cox, AJ; Gilbert, RE; Jandeleit-Dahm, K; Kelly, DJ | 1 |
6 review(s) available for simvastatin and Kidney Diseases
| Article | Year |
|---|---|
Effect of different types of statins on kidney function decline and proteinuria: a network meta-analysis.
Topics: Atorvastatin; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Kidney Diseases; Lovastatin; Network Meta-Analysis; Pravastatin; Proteinuria; Rosuvastatin Calcium; Simvastatin; Treatment Outcome | 2019 |
Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants.
Topics: Atorvastatin; Cardiovascular Diseases; Cause of Death; Chemical and Drug Induced Liver Injury; Double-Blind Method; Fluvastatin; Headache; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Lovastatin; Middle Aged; Muscular Diseases; Nausea; Neoplasms; Network Meta-Analysis; Placebos; Pravastatin; Randomized Controlled Trials as Topic; Risk Assessment; Rosuvastatin Calcium; Simvastatin; Withholding Treatment | 2019 |
Efficacy and safety of long-term treatment with statins for coronary heart disease: A Bayesian network meta-analysis.
Topics: Anticholesteremic Agents; Atorvastatin; Bayes Theorem; Coronary Disease; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Kidney Diseases; Lipids; Lovastatin; Muscles; Network Meta-Analysis; Patient Safety; Pravastatin; Quinolines; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2016 |
Pitavastatin: clinical effects from the LIVES Study.
Topics: Atorvastatin; Biomarkers; Cardiovascular Diseases; Cerebrovascular Disorders; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase IV as Topic; Comorbidity; Diabetes Mellitus, Type 2; Dyslipidemias; Glomerular Filtration Rate; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Kidney Diseases; Multicenter Studies as Topic; Muscular Diseases; Prospective Studies; Pyrroles; Quinolines; Risk; Simvastatin; Treatment Outcome; Triglycerides | 2011 |
Rosuvastatin-induced arrest in progression of renal disease.
Topics: Aged; Atorvastatin; Controlled Clinical Trials as Topic; Creatine; Disease Progression; Drug Administration Schedule; Female; Fluorobenzenes; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kidney; Kidney Diseases; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2004 |
Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Diabetic Nephropathies; Disease Progression; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; In Situ Hybridization; Kidney Diseases; Kidney Glomerulus; Lovastatin; Male; Nephrectomy; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Transforming Growth Factor beta | 1999 |
4 trial(s) available for simvastatin and Kidney Diseases
| Article | Year |
|---|---|
Have We Learnt all from IMPROVE-IT? Part I. Core Results and Subanalyses on the Effects of Ezetimibe Added to Statin Therapy Related to Age, Gender and Selected Chronic Diseases (Kidney Disease, Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease).
Topics: Aged; Anticholesteremic Agents; Chronic Disease; Diabetes Mellitus; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Male; Non-alcoholic Fatty Liver Disease; Simvastatin; Treatment Outcome | 2021 |
Efficacy of simvastatin in children with hyperlipidemia secondary to kidney disorders.
Topics: Child; Child, Preschool; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Hyperlipidemias; Hypolipidemic Agents; Kidney Diseases; Pilot Projects; Simvastatin; Time Factors; Treatment Outcome; Triglycerides | 2009 |
First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease.
Topics: Adult; Aged; Alanine Transaminase; Aspirin; Cardiovascular Diseases; Cholesterol, LDL; Chronic Disease; Creatine Kinase; Creatine Kinase, MM Form; Creatinine; Diabetic Nephropathies; Disease Progression; Feasibility Studies; Female; Hemorrhage; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Isoenzymes; Kidney Diseases; Kidney Transplantation; Lipids; Male; Middle Aged; Pilot Projects; Platelet Aggregation Inhibitors; Renal Dialysis; Renal Replacement Therapy; Simvastatin; Single-Blind Method; Thrombophilia; Treatment Outcome | 2005 |
The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD.
Topics: Anticholesteremic Agents; Azetidines; Chronic Disease; Drug Therapy, Combination; Ezetimibe; Female; Humans; Kidney Diseases; Male; Middle Aged; Simvastatin | 2006 |
18 other study(ies) available for simvastatin and Kidney Diseases
| Article | Year |
|---|---|
Hempseed (Cannabis sativa) offers effective alternative over statins in ameliorating hypercholesterolemia associated nephropathy.
Topics: Animals; Anti-Inflammatory Agents; Anticholesteremic Agents; Cannabis; Diet, High-Fat; Female; Free Radical Scavengers; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kidney Diseases; Lipid Metabolism; Liver; Oxidation-Reduction; Oxidative Stress; Plant Extracts; Rats, Wistar; Simvastatin | 2021 |
Graphene Oxide/Ag Nanoparticles Cooperated with Simvastatin as a High Sensitive X-Ray Computed Tomography Imaging Agent for Diagnosis of Renal Dysfunctions.
Topics: Animals; Biosensing Techniques; Contrast Media; Drug Carriers; Female; Graphite; Kidney Diseases; Metal Nanoparticles; Mice; Oxides; Silver; Simvastatin; Tomography, X-Ray Computed | 2017 |
Statin use in Australian children: a retrospective audit of four pediatric hospitals.
Topics: Adolescent; Atorvastatin; Australia; Child; Child, Preschool; Drug Utilization Review; Fluorobenzenes; Heptanoic Acids; Hospitals, Pediatric; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Infant; Kidney Diseases; Organ Transplantation; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2014 |
Simvastatin ameliorates renal lipidosis through the suppression of renal CXCL16 expression in mice with adriamycin-induced nephropathy.
Topics: Animals; Chemokine CXCL16; Chemokine CXCL6; Cholesterol; Disease Models, Animal; Down-Regulation; Doxorubicin; Endocytosis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Kidney Glomerulus; Lipidoses; Lipoproteins, LDL; Male; Mice, Inbred BALB C; NF-kappa B; Proteinuria; Signal Transduction; Simvastatin | 2015 |
Antioxidant activity of simvastatin prevents ifosfamide-induced nephrotoxicity.
Topics: Animals; Antioxidants; Biomarkers; Creatinine; Cytoprotection; Disease Models, Animal; Ifosfamide; Kidney; Kidney Diseases; Lipid Peroxidation; Male; Rats, Sprague-Dawley; Simvastatin | 2016 |
Simvastatin-induced rhabdomyolysis and acute renal injury.
Topics: Acute Disease; Female; Humans; Kidney Diseases; Middle Aged; Renal Dialysis; Rhabdomyolysis; Simvastatin; Treatment Outcome | 2008 |
Simvastatin ameliorates glomerulosclerosis in Adriamycin-induced-nephropathy rats.
Topics: Animals; Antibiotics, Antineoplastic; Disease Models, Animal; Doxorubicin; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-1beta; Kidney; Kidney Diseases; Male; NF-kappa B; Rats; Rats, Sprague-Dawley; Sclerosis; Simvastatin; Transforming Growth Factor beta1 | 2008 |
Hypercholesterolaemia induces early renal lesions characterized by upregulation of MMP-9 and iNOS and ET(A)R: alleviated by a dual endothelin receptor antagonist CPU0213 and simvastatin.
Topics: Animals; Body Weight; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Endothelin A Receptor Antagonists; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kidney; Kidney Diseases; Male; Matrix Metalloproteinase 9; Nitric Oxide Synthase Type II; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; RNA, Messenger; Simvastatin; Triglycerides; Up-Regulation | 2009 |
3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor simvastatin ameliorates renal fibrosis through HOXA13-USAG-1 pathway.
Topics: Adaptor Proteins, Signal Transducing; Animals; Bone Morphogenetic Protein 7; Bone Morphogenetic Proteins; Cell Line; Dogs; Female; Fibrosis; Homeodomain Proteins; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Mice; Mice, Inbred C57BL; Models, Biological; Polymerase Chain Reaction; Promoter Regions, Genetic; Protective Agents; Signal Transduction; Simvastatin | 2012 |
Simvastatin attenuates contrast-induced nephropathy through modulation of oxidative stress, proinflammatory myeloperoxidase, and nitric oxide.
Topics: Administration, Oral; Animals; Blood Urea Nitrogen; Calcium; Contrast Media; Creatinine; Glutathione; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iohexol; Kidney Diseases; Male; Nitric Oxide; Oxidative Stress; Peroxidase; Rats; Rats, Sprague-Dawley; Simvastatin | 2012 |
RhoA activation mediates phosphatidylinositol 3-kinase-dependent proliferation of human vascular endothelial cells: an alloimmune mechanism of chronic allograft nephropathy.
Topics: Cell Division; Chronic Disease; Cytoskeleton; Endothelium, Vascular; Gene Expression; Genes, MHC Class I; Humans; Kidney Diseases; Kidney Transplantation; Phosphatidylinositol 3-Kinases; Protein Prenylation; rhoA GTP-Binding Protein; Simvastatin; Transplantation Immunology | 2004 |
Simvastatin and L-arginine preserve renal function after ischemia/reperfusion injury.
Topics: Animals; Arginine; Cyclosporine; Drug Therapy, Combination; Glomerular Filtration Rate; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Kidney Diseases; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide; Random Allocation; Rats; Rats, Wistar; Reperfusion Injury; Simvastatin | 2005 |
Statins and aspirin in chronic kidney disease: what does the UK-HARP-I trial tell us?
Topics: Aspirin; Cardiovascular Diseases; Cholesterol; Chronic Disease; Disease Progression; Hemorrhage; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Kidney Transplantation; Peritoneal Dialysis; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Renal Dialysis; Research Design; Simvastatin; Treatment Outcome | 2005 |
Simvastatin promotes angiogenesis and prevents microvascular remodeling in chronic renal ischemia.
Topics: Angiogenic Proteins; Animals; Blood Pressure; Chronic Disease; Hypoxia-Inducible Factor 1, alpha Subunit; Ischemia; Kidney Diseases; Microcirculation; Neovascularization, Physiologic; Renal Artery Obstruction; Simvastatin; Swine; Transglutaminases | 2006 |
Simvastatin attenuates cisplatin-induced kidney and liver damage in rats.
Topics: Alanine Transaminase; Animals; Antineoplastic Agents; Aspartate Aminotransferases; Bilirubin; Blood Urea Nitrogen; Chemical and Drug Induced Liver Injury; Cisplatin; Creatinine; Female; Glutathione; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; L-Lactate Dehydrogenase; Liver Diseases; Male; Malondialdehyde; Peroxidase; Rats; Rats, Sprague-Dawley; Serum Albumin; Simvastatin | 2007 |
Simvastatin and fluvastatin reduce interleukin-6 and interleukin-8 lipopolysaccharide (LPS) stimulated production by isolated human monocytes from chronic kidney disease patients.
Topics: Cardiovascular Diseases; Cells, Cultured; Chronic Disease; Cytokines; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Indoles; Interleukin-6; Interleukin-8; Kidney Diseases; Lipopolysaccharides; Monocytes; Simvastatin | 2007 |
Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Contrast Media; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Length of Stay; Male; Middle Aged; Multivariate Analysis; Pravastatin; Preoperative Care; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2008 |
In vitro effects of simvastatin on tubulointerstitial cells in a human model of cyclosporin nephrotoxicity.
Topics: Aged; Cell Division; Cells, Cultured; Cholesterol; Cyclosporine; Female; Fibroblasts; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Cortex; Kidney Diseases; Kidney Tubules, Proximal; Male; Middle Aged; Permeability; Simvastatin; Sodium-Hydrogen Exchangers | 1999 |